Diquafosol
Names | |
---|---|
IUPAC name O1,O7-Di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate | |
Systematic IUPAC name O1,O7-Bis{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} tetrahydrogen tetraphosphate | |
Other names P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEMBL |
|
ChemSpider |
|
IUPHAR/BPS |
|
PubChem CID |
|
UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
Properties | |
Chemical formula | C18H26N4O23P4 |
Molar mass | 790.306 g·mol−1 |
Pharmacology | |
None | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references |
Chemical compound
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]
References
- ^ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan". April 16, 2010.
- ^ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.
{{cite journal}}
: CS1 maint: numeric names: authors list (link)
- v
- t
- e
(ligands)
P0 (adenine) |
| ||||
---|---|---|---|---|---|
P1 (adenosine) |
| ||||
P2 (nucleotide) |
|
(blockers)
CNTsTooltip Concentrative nucleoside transporters |
|
---|---|
ENTsTooltip Equilibrative nucleoside transporters | |
PMATTooltip Plasma membrane monoamine transporter |
(inhibitors)
XOTooltip Xanthine oxidase | |
---|---|
Others |
See also: Receptor/signaling modulators